Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer

JAMA Oncology

Volumn 1, Issue 5, 2015, Pages 582-591

  Antonarakis, Emmanuel S ^a,b   Lu, Changxue ^a   Luber, Brandon ^a   Wang, Hao ^a   Chen, Yan ^a   Nakazawa, Mary ^a   Nadal, Rosa ^a   Paller, Channing J ^a   Denmeade, Samuel R ^a   Carducci, Michael A ^a   Eisenberger, Mario A ^a   Luo, Jun ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ISOPROTEIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MESSENGER RNA; PHENYLTHIOHYDANTOIN; PROSTATE SPECIFIC ANTIGEN; TAXOID; TUMOR MARKER;

ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETIC PREDISPOSITION; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; MARYLAND; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR EMBOLISM; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC AGENTS; BALTIMORE; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PATIENT SELECTION; PHENOTYPE; PHENYLTHIOHYDANTOIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RISK FACTORS; RNA, MESSENGER; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85010711902     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1341     Document Type: Article

References (27)

1. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436-3448.
2. de Bono JS, Logothetis CJ, Molina A, et al; COU-AA-301 Investigators. Abiraterone and increased survival inmetastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
3. Scher HI, Fizazi K, Saad F, et al; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
4. Tannock IF, deWit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
5. de Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone formetastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
6. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl JMed. 2010;363(5):411-422.
7. Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival inmetastatic prostate cancer. N Engl J Med. 2013;369(3):213-223.
8. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12-23.
9. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67(3):470-479.
10. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61(3):549-559.
11. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-1038.
12. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469-5477.
13. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16-22.
14. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72(14):3457-3462.
15. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913-5925.
16. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2):483-489.
17. Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69(21):8386-8394.
18. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70(20):7992-8002.
19. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses inmetastatic prostate cancer. Cancer Res. 2011;71(18):6019-6029.
20. Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on themove: boarding the microtubule expressway to the nucleus. Cancer Res. 2012;72(18):4611-4615.
21. Kirby BJ, Jodari M, Loftus MS, et al. Functional characterization of circulating tumor cells with a prostate-cancer-specificmicrofluidic device. PLoS One. 2012;7(4):e35976.
22. Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74(8):2270-2282.
23. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
24. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
25. de Leeuw R, Berman-Booty LD, Schiewer MJ, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21(4):795-807.
26. Plymate SR, Bhatt RS, Balk SP. Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2. Cancer Cell. 2015;27(2):158-159.
27. van Soest RJ, de Morrée ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol. 2015; 67(6):981-985.